PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$3.73B
1-Year Est. Return
133.76%
This Fund
S&P 500
1 Year Est. Return
+133.76%
AUM
$3.38B
AUM Growth
+$1.04B
(+44%)
Holding
39
Top Buys
| 1 | +$95.9M | |
| 2 | +$93M | |
| 3 | +$75.7M | |
| 4 |
CDTX
Cidara Therapeutics
CDTX
|
+$61.3M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$57.6M |
Top Sells
| 1 | +$85.3M | |
| 2 | +$84.2M | |
| 3 | +$57.3M | |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$41.5M |
| 5 |
LENZ
LENZ Therapeutics
LENZ
|
+$23.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
EyePoint Inc
EYPT
$1.52B
| $28.6M | 0.84% |
+2,005,365
|
|
||
27
Tango Therapeutics
TNGX
$1.55B
| $25.9M | 0.77% |
+3,086,184
|
|
||
28
Amylyx Pharmaceuticals
AMLX
$1.55B
| $25.8M | 0.76% |
+1,900,000
|
|
||
29
Spyre Therapeutics
SYRE
$3.15B
| $24.6M | 0.73% |
1,467,266
-403,179
|
|
||
30
Dyne Therapeutics
DYN
$2.4B
| $24M | 0.71% |
+1,898,950
|
|
||
|
BBOT
31
BridgeBio Oncology
BBOT
$779M
| $21.6M | 0.64% |
+1,866,141
|
|
||
32
Disc Medicine
IRON
$2.43B
| $16.4M | 0.48% |
247,716
-963,255
|
|
||
33
Structure Therapeutics
GPCR
$4.45B
| $10.4M | 0.31% |
+372,869
|
|
||
|
CBIO
34
Crescent Biopharma
CBIO
$341M
| – | – |
-642,721
|
|
||
35
Immatics
IMTX
$1.32B
| – | – |
-3,144,157
|
|
||
|
36
MoonLake Immunotherapeutics
MLTX
$1.25B
| – | – |
-878,323
|
|
||
37
State Street SPDR S&P Biotech ETF
XBI
$8.08B
| – | – |
0
|
|
||
|
YMAB
38
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-4,236,346
|
|
||
|
ONC
39
BeOne Medicines Ltd
ONC
$32.9B
| – | – |
-347,787
|
|